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February 21, 2008 
Dr. Chris Penland 
Director of Research 
Cystic Fibrosis Foundation 
6931 Arlington Rd. 
Bethesda, MD 20814 
Dear Chris: 
The following constitutes the final scientific report for our grant number MCCARTO6P0, which 
was graciously supported by the Foundation under the CFF/NIH bridge funding program. 
We requested support from the Foundation on December 22, 2005, following the failure to 
receive support from the NIH for our grant entitled "Peptide Inhibitors Probe Structure and Function in 
Chloride Channels" (1-R01- DK075016-01). The goals of the NIH project were to isolate and achieve 
initial characterization of two different peptide toxins from scorpion venom: one which inhibits CFTR 
and another which inhibits CIC-2 voltage-gated chloride channels. At the time of submission to the 
Foundation in December, we already had isolated the toxin active at CIC-2 (see Thompson et al., 
2005), but had not yet determined the complete sequence. We had not yet isolated the toxin active at 
CFTR. The major goal of the CFF-NIH grant submitted for Foundation support was to complete the 
isolation of the toxin active at CFTR. The Foundation provided one year of support at a budget of 
$75,000; funding period was 07-01-06 through 06-30-07, with a no-cost extension to 09-30-07. 
I. 	Lay Abstract 
The protein defective in Cystic Fibrosis, CFTR, functions as a chloride channel in the outer 
membranes of cells in the airway. Over the past decade, we have greatly increased our 
understanding of how this protein works in normal airway cells, with the hope that this information 
could help us understand how to fix CFTR in the airway cells of CF patients. In order to gain deeper 
insight into how CFTR works, and how the structure of this protein relates to its function, we need to 
develop molecular probes that can serve as experimental tools. Similar studies of other ion channel 
proteins, such as potassium channel proteins and sodium channel proteins, have been aided by the 
identification of peptide toxins that interact with these proteins with very high specificity. Many such 
peptide toxins, proteins which are much smaller than the ion channel proteins with which they interact, 
have been isolated from the venom of animals such as scorpions, snakes, spiders, and other animals 
that rely on these toxins for either their defense or feeding. However, never before has a peptide 
toxin been identified that interacts with a specific chloride channel protein such as CFTR. 
The goal of this project was to isolate a peptide toxin that m ight interact with CFTR. We found 
previously that the venom of the Giant Yellow Israeli Scorpion contained a peptide component wh ich 
binds to CFTR, and changes its function. Based on this exciting observation, we used a variety of 
molecular separation techniques to isolate the active peptide from among the hundreds of other 
peptides that comprise this scorpion's venom. The chemical separation techniques we used included 
separating the components of venom according to their hydrophobicity (essentially, how sticky they 
are), along with separating the components according to their molecular size. These steps were 
guided by testing each fraction of the venom, pr oduced by the separation techniques, to ask how 
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good it was at changing the function of the CFTR channel when it is studied using high-resolution 
electro-physiology techniques. This way, we could follow the activity of the active corn ponent through 
the separation process. 
The end result of this effort was the isolation of a novel peptide, which has a sequence that has never 
before been described, but is shaped very much like the peptide toxins that are known to interact with 
potassium or sodium channel proteins. However, this is the first peptide toxin ever found that 
interacts with a specific chloride channel protein. We named the toxi n GaTx1. This toxin interacts 
with the CFTR channel with higher strength than almost all other compounds that are known to 
interact with CFTR, and is absolutely specific --we have not found any other protein that interacts with 
GaTx1. We are now using GaTx1 to understand how CFTR functions, and particularly how CFTR 
changes its shape during the opening and closing of the chloride channel pathway. Furthermore, 
because GaTx1 appears to interact with the parts of CFTR that are defective in most mutated 
versions of the protein, it is possible that this small peptide could help hide the fact that CFTR is mis-
folded, leading to an increase in functi onal CFTR protein in the airway cells. This would be expected 
to help minimize the consequences of the defect in the CFTR protein. 
II. 	Detailed Report 
A. Specific Aims (for the CFF-NIH proposal): 
Specific Aim #1. Isolate the toxin active at CFTR and confirm biological activity.  Toxin 
isolation will be completed by coupling separations chemistry, using reversed-phase HPLC, with 
electrophysiological bioassays. We will then use the isolated toxin to confirm its mechanism of action, 
to construct true dose-response curves, and to determine the forward and reverse kinetics of 
interaction with CFTR channels. 
Specific Aim #2. Characterize the peptide toxin using proteomic approaches.  We will 
determine the molecular weight of the toxin, sequence it, i dentify any post-translational modifications, 
and then compare the primary sequence to those of known toxins. •We will also construct homology 
models, to guide structure-function studies. 
Specific Aim #3. Produce the peptide toxin exogenously. We will isolate or synthesize cDNA 
encoding the peptide toxin, and use this construct for the preparation of recombinant toxin by bacterial 
expression. We will also produce the toxin by solid phase chemistry, and will then determine the 
efficacies of both the recombinant and synthetic toxins in electrophysiological experiments. These 
steps are necessary to facilitate the production and study of mutant peptide toxins. 
Specific Aim #4. Identify the structural elements underlying biological activity.  Informed by 
the results of the modeling studies of Aim#2, we will design, prepare, and test mutant versions of the 
toxin to determine what structural features confer efficacy and selectivity against its target. These 
experiments may lead to identification of modifications that can improve efficacy, in order to make this 
molecular probe even more powerful. 
B. Studies and Results 
1. 	Progress toward overall goals 	 Venoms from snakes, scorpions, marine snails, 
and spiders are rich sources of peptide toxi ns that have proven to be of great value in the functi onal 
exploration of voltage-gated and ligand-gated cation chann els. 	Unfortunately, although several 
potential chloride channel toxins have been identified, peptide inhibitors of chloride channels of known 
molecular identity have not been described. In 1992, Strichartz and colleagues described the 
isolation of chlorotoxin (CITx), a small basic peptide capable of inhibiting low-conductance CI 
channels from rat colon or rat brain reconstituted into lipid bilayers. However, CITx has not been 
found to inhibit any anion channel of known mol ecular identity; indeed, its only known target is a 
matrix metalloprotease. 
Prior to our initiation of this project, we showed that venom from the scorpion Leiurus 
quinquestriatus hebraeus inhibits CFTR by binding to the channel from the cytoplasmic side (Fuller et 
al., 2004); we also showed that CITx does not inhibit CFTR. We then showed that the corn ponent (or 
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Figure 1: Isolation of the active peak. (a) 
Representative RP-HPLC chromatogram of 
fraction C-gf#30-32. Individual peaks were 
collected and tested for activity. The arrow 
indicates the active peak, peak #6. (b) 
Representative single channel trace in the absence 
and presence of peak #6. The isolated toxin 
inhibits CFTR by increasing the interburst closed 
duration. 
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channel only during closed states (Fuller et al., 2005). Our characterization of this activity of venom 
served a major purpose of forming the bioassays that we would then use for the isolation of the active 
component(s). 
We made significant progress toward the goals of this project, both before and since the CFF 
funding began in July 2006. Most importantly, we have completed the isolation of the toxin that 
inhibits CFTR, completing Aims 1 and 2. 
2. 	Progress toward Aim #1: 	Sequential 
purification of components of scorpion venom 
using size-exclusion chromatography and 
reversed-phase HPLC (RP-HPLC) resulted in 
the isolation of a single peptide whose 
biological activity was sufficient to recapitulate 
the interburst inhibitory activity of crude venom. 
This was accomplished by combining these 
chemical separation approaches with the 
difficult bioassay of recording of CFTR channel 
current from membrane macropatches and 
single-channel patches. Single-channel 
recordings of WT-CFTR activity in the absence 
and presence of the active final fraction 
indicated that the fraction inhibited CFTR by 
inducing long-lived interburst closings (Fig. 1). 
The active fraction caused a 58.2 ± 11.3 % 
decrease in P o from 0.19 ± 0.06 in control 
conditions to 0.06 ± 0.004 (n = 3) in presence of 
the active fraction. From these results we 
concluded that this fraction contained a peptide 
toxin which inhibited WT-CFTR; we named this 
toxin "GaTx1". 
Figure 2 shows data from a single-
channel recording of WT-CFTR in the absence 
of toxin (upper and lower traces) and in the 
presence of 60 nM GaTx1 (middle trace), indicating reversible inhibition. Exposure of single CFTR 
channels to GaTx1 in an inside-out patch led to the introduction of very long closed states without 
affecting the duration of the open states. Toxin-induced closed durations are very long; the mean 
toxin-induced closed duration in this expe riment was >5 seconds. However, evident in the dwell-time 
distribution (Fig. 2e) are toxin-induced closed states that last nearly a minute. Hence, GaTx1 interacts 
with CFTR —1,000-fold longer than most known blockers, and longer than the thiazolidi none CFTRinn-
172, the best CFTR inhibitor found to date. This intimate interaction means that GaTx 1 will be a very 
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Figure 2: Native GaTx1 inhibits CFTR by increasing the interburst closed duration. (a) Representative 
single channel trace of WT-CFTR in the absence and presence of 0.1 mg/mL equivalent GaTx1. Open 
probability was significantly reduced in the presence of GaTxl. (b -e) Burst analysis of CFTR open 
durations in the absence (b) and presence (c) of GaTx1, and CFTR closed durations in the absence 
(d) and presence (e) of GaTx1. For this analysis, the record after toxin washout was used as control, 
to account for any potential loss of channel activity due to rundown. Toxin increased the interburst 
closed time, but had no effect of CFTR open duration. A concentration of 0.1 mg/mL venom 
equivalent, as shown in this experiment, was determined by amino acid analysis to provide 60 riM 
native GaTx1. 
3. 	Progress toward Aim #2: 	Initial characterization of the active peptide contained in the final 
chromatographic fraction was accomplished by subjecting a small aliquot of the material to MALDI-
TOF analysis. A single peptide was identified with a molecular mass of 3,674.6 Da (Fig. 3a). 
Additional, less abundant peaks with similar mass were also identified that likely represent different 
oxidative states of the same toxin; a doubly charged species also was observed ( m/z = 1,838.8 Da). 
The peptide in this fraction then was subjected to automated amino terminal sequencing following 
destruction of all putative disulfide bridges by reduction with DTT and alkylation of free cysteines by 
iodoacetamide. The reduction and alkylation of the native toxin resulted in an increase in molecular 
mass to 4,138.5 Da as determined by MALDI-TOF, which is in agreement with the modification of 
eight cysteines; expected m ass = 4,138.6 Da. The primary sequence was determined to be: 1 CGP-
CFT-TDH-QME-QKC-AEC-CGG-IGK-CYG-PQC-LCN-R 34 , including C-terminal amidation as the only 
post-translational modification other than form ation of disulfide bridges. The calculated mass of the 
isolated toxin based upon primary sequence and assuming post-translational C-terminal amidation 
was in close agreement with the mass determined by MS. The same toxin has been purified from 
multiple batches of scorpion venom. Because the sequencing yield from the full-length modified 
peptide dropped below the 1-pmol level toward the very C-terminus, an aliquot of the modified toxin 
was digested with Lys-C protease which is specific for Lys-Xxx peptide bonds. The digest was 
separated by RP-H PLC and the resulting three fractions were manually collected and subjected to 
Edman sequencing. The sequences of the three fragments corresponded to: (1) N-term.: 
CGPCFTTDHQMEQK; (2) Middle: CAECCGGIGK; and (3) C-term.: CYGPQCLCNRamide. The C-
terminal fragment was further analyzed by ESI-MS/MS, yielding a molecular ion of 1,325.5 Da, which 
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2 C1 Tx-b 94.1* 
3 C1Tx-c 94.1* 
4 BmKCT 82.4% 
5 BmK 41-2 79.4% 
6 P2 79.4% 
7 Bs14 76.5% 
8 BeI4 76.5* 
9 C1Tx-a 75.0% 
10 C1Tx 75.0% 
11 0e8 75.01 
12 	I5A 73.5% 
13 BeI5 70.6% 
14 Lqh 8/6 68.8% 
15 	I1 65.6* 
16 ButaIT 65.6% 
17 	13 62.5% 
18 BtITx3 56.2% 
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The ESI-MS/MS data also confirmed the presence of three carboxymethyl-Cys residues in this 
fragment. Hence, the sequence listed above has been verified. 
d 
1 41— Loop 1 	4.1 	 14— 	Loop 2 	 -$1 	I Loop 3 1 
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Figure 3: Proteomic characterization of GaTx1. (a) MALDI-MS spectrum of peak #6, showing a 
prominent mass of --3.7 kDa. (b) Alignment of the GaTx1 sequence with other scorpion toxins shows 
that GaTx1 is a novel peptide. (c) Comparison of the CITx NMR structure (left) and the GaTx1 
homology model (right), in three orientations. Disulfide bridges are shown in the upper panels. (d) 
Sequence alignment of GaTx1 with the sequences of chlorotoxin (CITx) and charybdotoxin (ChTx). 
Predicted secondary structure is indicated above the sequences while disulfide bridge linkage 
between conserved cysteines is indicated below. The dashed line indicates the disulfide bridge absent 
in ChTx. 
Comparisons of the primary sequence with those of other previously characterized known or 
putative peptide toxins suggested that the isolated toxin, which we named GaTx1, is novel, with C ITx-
d recognized as its closest relative (Fig. 3b). CITx-d is not known to inhibit any ion channel; indeed, 
the sequences of CITx-b, -c, and -d are speculative, being predicted from the sequences of cDNAs 
cloned from scorpion venom gland. The primary sequence of GaTxl, the molecular mass, and the 
presence of four disulfide bridges between conserved cysteines place this toxin in the family of 
insectotoxins active at K + channels (which includes charybdotoxin) and putative toxins active at CI -
channels. GaTx1 bears 75% sequence identity to CITx, but is smaller by — 400 Da. The calculated pl 
values for GaTx1 and CITx are 6.71 and 8.13, respectively. 
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Figure 4: Synthetic GaTx1 inhibits CFTR. (a) 
Representative multi-channel trace of Flag-cut-AR-CFTR in 
the absence and presence of synthetic 250 nM GaTx1. (b) 
Window current over three-minute widows was measured 
in the presence of 0.2 mM MgATP under control conditions, 
and in the presence of 0.2 mM ATP (closed circles), 0.2 
mM ATP plus 50 nM GaTx1 (open triangle), or 0.2 mM ATP 
plus 250 nM GaTx1 (open square), and normalized to 
control conditions. Each point represents a single patch 
where macroscopic window current was calculated within 
five windows each under control and experimental 
conditions. 
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A homology model of GaTx1 was created, based on the known NMR structures of CITx and 
insectotoxin 5A. Figure 3c shows the NMR structure of CITx and the homology model of GaTx1, in 
three orientations. The two structures are quite similar in shape and secondary structure, although 
GaTx1 has three regions of anti-parallel 13-strand compared to two in CITx; the extra strand is at the 
immediate N-terminus. The 15A toxin structure (not shown) includes three 13-strands and a longer ct-
helix compared to CITx. GaTx1 is also somewhat more compact than CITx, partly due to the insertion 
of two amino acids C-terminal to the a-helix in CITx, and due to the lack of defined secondary 
structure in the first loop of CITx, resulting in a bulge of relatively disordered sequence at the N-
terminal end of the a-helix in CITx. Figure 3d identifies the borders of regions of predicted secondary 
structure for GaTx1, and corn pares the GaTx1 sequence with that of CITx and charybdotoxin (ChTx). 
While the most striking primary structure differences between short insectotoxins (including all three of 
these) and the longer toxins that inhibit Na + channels and Ca 2+ channels are the lengths of loops 2 
and 3, the major differences between GaTx1 (which inhibits CFTR) and CITx (which does not) are in 
the a-helix. Hence, GaTx1 is the first peptide toxin ever found that inhibits an anion channel of known 
molecular identity. It is also the first toxin known to inhibit an ABC Transporter, the superfamily of 
which CFTR is a member. The GaTx1 sequence has been deposited with Uni Prot as entry # P85066. 
4. 	Progress toward Aim #3: 	To confirm 
that the inhibitory activity in venom could be 
ascribed to the sequenced toxin, and did not 
arise from a contaminant, we prepared GaTx1 
by solid-phase chemistry. After purification by 
HPLC, MS analysis indicated that the synthetic 
linear peptide has a mass in agreement with the 
theoretical mass for the linear form (i.e., all 
disulfides reduced to sulfhydryls) of the native 
toxin. The linear peptide was subjected to 
oxidative cyclization and refolding was 
performed over three days under equili brating 
conditions, in order to promote the formation of 
the most stable disulfide bridges. The mass of 
the folded synthetic peptide was w ithin one 
a.m.u. both of the theoretical expected value 
and of the observed mass of the native toxin 
isolated from venom. 
We used multichannel recordings from 
oocytes expressing Flag-cut-AR-CFTR to test 
for activity of synthetic GaTx1 (Fig. 4), taking 
advantage of the insensitivity of this mutant 
CFTR to dephosphorylation-mediated rundown; 
we showed previously that Flag-cut-AR-CFTR 
is inhibited by venom to a similar degree as 
WT-CFTR. Because GaTx1 binds channels 
in the closed state, we used intracellular 
solution containing only 0.2 mM ATP, which 
leads to reduced open probability, thus 
increasing the likelihood of a toxin binding 
event. In the presence of 250 nM synthetic 
GaTx1, channel current was reduced by 71.1 
± 2.6% (p< 0.001). With 50 nM synthetic 
GaTx1, channel activity was reduced by 56.2 
± 5.0% (p< 0.001), suggesting that the IC 50 for 
synthetic GaTx1 under these conditions may 
a 
0.2 mM ATP 
0.2 mM ATP 250 nM GaTx1 
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be —20 nM. Since the end of the funding period, we have been doing more experiments to construct 
a true dose-response curve. We point out that the strong state-dependence of action exhibited by 
GaTx1 means that the apparent IC 50 for the toxin will be very protocol dependent; under conditions 
that increase P o , the apparent IC 50 will be elevated. 
Because the toxin produced exogenously by solid-phase chemistry has worked so well, we 
chose not to attempt to make GaTx1 using recombinant methods. This decision is also supported by 
the facts that: (1) we obtain large amounts of toxin from a single synthesis, and (2) the synthetic 
GaTx1 elutes from a silica RP-HPLC column with the same retention time as the major component of 
the active fraction of venom, suggesting that they are similar in hydrophobicity. 
5. Summary of progress 	In short, we have com pleted the most important parts of Aim 1, 
all of Aim 2, and all of Aim 3. 
6. Plans for the near term 	We will continue experiments with the wildtype synthetic GaTx1 
to construct true dose-response curves under a variety of conditions (i.e., ATP concentrations), and 
then will perform more single-channel experiments to better quantify the kinetics of interaction 
between toxin and chann el. With the help of our colleagues at Calgary, we also will begin to produce 
mutant toxins for the experiments proposed under Aim 4. 
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C. 	Grant submission 
Consistent with CFF policy, we submitted a revised proposal to the NIH for the next phase of work 
with GaTx1 within the first month of Foundation funding. Principal Investigator, National Institutes of 
Health, "Peptide inhibitors probe structure and function in chloride channels", 1-R01-DK075016-01A1. 
The proposal earned a score of 1.6 at study section, but did not reach funding. A r esubmission is 
planned for this year. 
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C. 	Presentations 
1) "Unique tools for the study of CFTR and C1C-2 airway epithelial chloride channels," 
Department of Pediatrics, Emory University School of Medicine, September 21, 2006. 
2) "Finally: two novel peptide toxins active at chloride channels, CFTR and C1C-2," 
Membrane Biophysics Subgroup of the Biophysical Society, Baltimore, MD, March 
3, 2007. 
D. 	News release (CFF-approved) 
http://wwwoatech.edu/newsroom/release.html?id=1717   
and subsequent news releases, such as: 
http://www.eurekalertorci/pub releases/2008-02/giot-pdi021408.Dhp  
http://www.sciencedailv.com/releases/2008/02/080214114521.htnn  
http://www.sciencebloci.cornicms/scorpion-venom-may-hold-key-cystic-fibrosis-fix-15478.html 
IV. 	Intellectual property/Patents 
In May of 2006, we submitted a provisional patent application through Georgia Tech's Office of 
Technology Licensing (GT RC project number 3872, filed May 19, 2006). This was necessary 
because Matt Fuller, the then-PhD student whose dissertation work resulted in isolation of the toxin, 
was scheduled to defend his dissertation in late May. We wanted to be sure to protect this piece of 
technology before making any public dissemination. At that time, we had not yet begun using the 
support for this project provided by the Foundation (in essence, we completed the isolation before 
starting to use the CF F's support). However, the subsequent characterization of GaTx1 has been 
fully supported by our CFF grant. Therefore, we imagined that the Foundation would be interested in 
helping support the submis sion of a full patent for this technology. With input from you (Penland) and 
Melissa Ashlock, Diane Wetmore arranged to help with the costs of filing. A full patent application 
was filed as follows. We also received support from the CFF for help with filing costs for a patent 
application on GaTx2, a toxin which inhibits C IC-2 channels with incredibly high affinity. 
1) "ABC Transporter Ligand", for a peptide toxin that interacts with the CFTR chloride 
channel, filed May 18, 2007, International PCT number PCT/US07/69243. Inventors: 
N.A. McCarty, M.D. Fuller, and J. Kubanek. Patent held by Georgia Tech Research 
Corporation. 
2) "C1C Channel Ligand", for a peptide toxin that interacts with the C1C-2 chloride 
channel, filed July 12, 2007, International PCT number PCT/US07/73325. Inventors: 
N.A. McCarty, C.H. Thompson, and J. Kubanek. Patent held by Georgia Tech 
Research Corporation. 
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This concludes our final scientific report. Please let me know if you require anything else. We greatly 
appreciate the Foundation's support of our work. 
Best regards, 
Nael A. McCarty, Ph.D. 
Associate Professor of Pediatrics 
And Senior CF Scientist 
Emory University 
Associate Director for Research, 
Emory University Cystic Fibrosis Center 
Adjunct Professor of Biology, Georgia Tech 
Adjunct Professor of Physiology, Emory University 
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